✦ LIBER ✦

Small cell carcinoma of the ovary: clinical and biological study

✍ Scribed by Seiji Isonishi; Hiroshi Nishii; Motoaki Saitou; Makoto Yasuda; Takako Kiyokawa; Masaharu Fukunaga; Hiroshi Ishikawa; Tadao Tanaka

Publisher: Springer
Year: 2008
Tongue: English
Weight: 384 KB
Volume: 13
Category: Article
ISSN: 1341-9625
DOI: 10.1007/s10147-007-0698-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Small cell neuroendocrine carcinoma of t

Small cell neuroendocrine carcinoma of the ovary

✍ Masaharu Fukunaga; Yasuhiko Endo; Yoshio Miyazawa; Shinichiro Ushigome 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 719 KB

Small-cell carcinoma of the ovary in per

Small-cell carcinoma of the ovary in peritoneal fluid

✍ Suzanne M. Selvaggi 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 478 KB

Large-cell variant of small cell carcino

Large-cell variant of small cell carcinoma of the ovary with hypercalcaemia

✍ G. Di Vagno; G. A. Melilli; G. Cormio; D. Piscitelli; A. Ciampolillo; L. Resta; 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 18 KB

Biological markers and small cell carcin

Biological markers and small cell carcinoma of the lung. A clinical evaluation of urinary ribonucleosides

✍ T. Phillip Waalkes; Martin D. Abeloff; David S. Ettinger; Kwang B. Woo; Charles 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 808 KB

Five minor base ribonucleosides, primarily degradation products of transfer ribonucleic acid (tRNA), were evaluated as potential biological markers for patients with small cell carcinoma of the lung. The urinary concentration for pseudouridine, 1-methyladenosine, 1 -methylinosine, N2-methylguanosine

Clear cell carcinoma of the ovary

✍ Khalid Hameed; Michael R. G. Burslem; W. R. Carl Tupper 📂 Article 📅 1969 🏛 John Wiley and Sons 🌐 English ⚖ 781 KB

A phase II clinical study of mAMSA in sm

A phase II clinical study of mAMSA in small cell carcinoma of the lung

✍ P. J. Dady; A. -P. Sappino; A. Rudd; I. E. Smith 📂 Article 📅 1981 🏛 Springer 🌐 English ⚖ 167 KB

Thirteen patients with small cell carcinoma of the bronchus that had become resistant to conventional chemotherapy were given 4'-(9-acridinylamino)methanesulphon-m-anisidide (mAMSA) at a dose of 90 or 120 mg/m2 at 3-week intervals. Twenty percent of the courses at 90 mg/m2 produced marked myelosuppr